The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Extracts from recent RNS's
The Company also continues to evaluate M&A opportunities and will consider additional bolt-on acquisitions to add strategic assets and functionality to the expanding Group.
The Company's lead business units comprise of Primerdesign and Lab21 Products.
Development of an antibody lateral flow test for COVID-19
On 29 September 2020, Novacyt announced the launch of its IgG specific antibody test for use in central laboratory testing. The Company is also working on developing an IgG antibody lateral flow test (LFT) for use as a rapid antibody test for professional use. An LFT is an easy-to-use diagnostic device used to confirm the presence or absence of a pathogen or biomarker. The product is expected to launch during Q1 2021 and is expected to take approximately 20 minutes or less to give a result.
@NFR, Ok Thanks for correction. My understanding is that the high throughput test system has also been upgraded reducing turnaround time?
Quickdraw/NewFormsResearch
Thanks for the link to Perkin Elmer material on seeking alpha. I expect extension would be small for them as they say if it would only cover support & reagents now and the sale of more equipment given their turnover is $3.7bn.
Incidentally, the footnote on Bidstat award has a link to redacted contract with PerkinElmer that says the DHSC has the right to a 6 month extension at their option based on written notice of 8 weeks (which would be 3rd Feb) & their interview was 2nd Feb.
Perkin Elmer - Redacted
https://atamis-1928.cloudforce.com/sfc/p/0O000000rwim/a/4J000000kEaZ/LbBy7mhRzDh...
Lighthouse = COVID HT updated reducing turnaround time = Promated. With testing that can identify the ‘ones of concern’ which the other tests can’t do ?? Please correct my logic. If NCYT have an edge then it is game on as the race to contain the surge testing gets more desperate.
Appreciate the thumbs up try2buy low. I don't know specifics of a Lighthouse lab kit out. It definitely wouldn't involve the use of q's.
From recall the Cambridge, AstraZeneca lab utilised some tailored manufacturing equipment to enable COVID HT-Direct test and which removed the RNA extraction process
So if HT-Direct were to be adopted by a second Lighthouse Lab this production change would be required. I'd imagine a revision to an existing lab over creation of a new one.
The planned Lemington Spar lab would make sense to adopt HT-Direct as its in the process of being brought on line.
SNPsig is a second stage test, which is run against all postive tests to screen for know variants with flagged postive tests with unknown genetic makers then being sent for sequencing which is mostly undertaken by Oxford Nanopore. I'm not sure if SNPsig is compatible with the high-throughput configuration of the Cambridge Lighthouse
In respect of the PerkinElmer comments they were taken from their Q4 Earnings call 02/02.
https://seekingalpha.com/article/4402947-perkinelmer-inc-pki-ceo-prahlad-singh-on-q4-2020-results-earnings-call-transcript
NewFormsResearch - I have found your comments helpful & thought provoking.
Can I ask a couple of questions please - what was the source of your quote from PerkinElmer? I have my spreadsheets out modelling scenarios, do you have a view or guide for estimating the amount of equipment a new Lighthouse Lab would require from NCYT? Would NCYT purpose build a lab or is it better to assume provision of a number of qs? I wonder if they will consider expansion of variant testing facilities in all Lighthouse Labs as a national strategy against variants running along side massive volume, (& mainly LF) tests.
If i recall we discussed the BID STATS contract issued in Nov 20. It was 20bn split supply and services
15 bn split by 100 Suppliers.
https://bidstats.uk/tenders/2020/W45/738131985
So for Microgen that was possibly 150m over 4 years, 37.5m a year?
If that was the case then i would expect an RNS for that order? But we never heard anything since??? or have i missed something?